CTS-1027 is an oral, small molecule compound that inhibits the activity of key members of a class of protease enzymes, the matrix metalloproteinases (MMPs).
The trial will evaluate the safety, tolerability, and antiviral activity of the triple combination after up to 48 weeks of therapy.
The trial will also assess if higher dose levels of CTS-1027 will improve on previously observed results.
The placebo-controlled, multicentre, double-blind, randomised trial will enroll approximately 260 patients who will receive Peginterferon Alfa-2a (Pegasys) and ribavirin (Copegus) with or without CTS-1027.
The trial will be conducted at up to 50 medical centres across the US.